SRR and Alzheimer disease: The AD model overexpresses human Aβ42 peptides in the nervous system and harbors degenerative neuronal phenotypes in a dose- and age-dependent manner [45], and the SRR agonist was treated as soon as the AD Drosophila emerged from the pupal case to simulate the early stage of AD, where the D-serine levels might be decreased.